Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN LISPRO & INSULIN LISPRO PROTAMINE

All products: general benefit

Other products in the same Health Canada class (A10AD) — coverage varies; not interchangeable

  • Insulin neutral + isophane human biosynthetic (Novolin ge 30/70): general benefit
  • Insulin aspart + insulin aspart protamine (NovoMix 30 Penfill): general benefit
  • Insulin human biosynthetic + isophane (Humulin 30/70): general benefit

Humalog Mix25 · DIN 02240294 · 25% & 75% · injectable suspension, 5 x 3 mL

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Humalog Mix25 · DIN 02240294 Manufacturer: Eli Lilly Canada Inc.; listing date 2000-04-17 Health Canada: Marketed since 1999-07-05 · brand HUMALOG MIX 25 (CARTRIDGE) · ATC A10AD04 INSULIN LISPRO · form Suspension · route Subcutaneous · ingredients INSULIN LISPRO PROTAMINE SUSPENSION 75 UNIT/ML, INSULIN LISPRO 25 UNIT/ML · company Eli lilly canada inc · schedule Schedule d
Check this DIN again · Health Canada product record

Humalog Mix25: Formulary list price $74.6900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $74.6900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63832 · Verify on the e-Formulary ↗ (DIN 02240294)

Source record
DIN 02240294: Humalog Mix25 Raw flags: insOH=Y, sec3=Y Item: 682016033; group id 786; item number 1911; lccId None; manufacturer id LIL Source form: Inj Susp-5x3mL Pk; strength: 25% & 75% Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $74.6900; ministry $74.6900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240294 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63832
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240294
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:16 Insulins (Pre-Mixed)) and how they are covered

Matched class: 68:20:16 Insulins (Pre-Mixed)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70% 68:20:16 Insulins (Pre-Mixed)

INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Susp-10mL Pk, Inj Susp-5x3mL Pk

INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%

· 1 products · General benefit · strengths: 100U/mL · Inj Susp-5x3mL Pk

INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70%

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Susp-10mL Pk, Inj Susp-5x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:16
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: diabetes, diabetes requiring daily doses of more than 20 units of fast-acting insulin, the initial stabilization of diabetes
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN HUMAN BIOSYNTHETIC INSULIN LISPRO · Limited Use, codes 646 (1), General benefit (4) INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02229704; fetched 2026-09-10 Product monograph HUMALOG insulins are also indicated for the initial stabilization of diabetes mellitus. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02229704; fetched 2026-09-10 Product monograph HUMALOG 200 units/mL KwikPen (insulin lispro injection) is reserved for the treatment of patients with diabetes requiring daily doses of more than 20 units of fast-acting insulin. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02229704; fetched 2026-09-10 Product monograph INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024217; fetched 2026-09-10 Product monograph INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024225; fetched 2026-09-10 Product monograph INSULIN ASPART · Limited Use, codes 646 (1), General benefit (4) 1 Indications NOVORAPID® (insulin aspart) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10 Product monograph • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. NOVORAPID® should normally be used in regimens together with an intermediate or long-acting insulin. NOVORAPID® (10 mL vials) may also be used for continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for insulin infusion. PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10 Product monograph INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70% · General benefit  The treatment of adult patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00062479.PDF; date JUL 11, 2017; DIN 02265435; fetched 2026-09-10 Product monograph INSULIN HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024233; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. HUMALOG insulins are also indicated for the initial stabilization of diabetes mellitus. HUMALOG (insulin lispro injection) is a fast-acting insulin analogue and is for use in conjunction with a longer HUMALOG, HUMALOG 200 units/mL KwikPen, HUMALOG MIX25, HUMALOG MIX50 Page 3 of 63 acting insulin, such as HUMULIN N (insulin isophane (rDNA origin) NPH), except when used in a subcutaneous insulin infusion pump. HUMALOG 200 units/mL KwikPen (insulin lispro injection) is reserved for the treatment of patients with diabetes requiring daily doses of more than 20 units of fast-acting insulin. https://pdf.hres.ca/dpd_pm/00063278.PDF PM date: April 12, 2021 Source product: HUMALOG MIX 25 (CARTRIDGE); DIN 02240294; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.